A seven amino acid peptide (PEP7) is encoded within a short open reading frame (sORF) within exon 2 (E2) in the 5'-leader sequence (5'LS) upstream of the rat angiotensin 1a-receptor (rAT 1a R) mRNA. A chemically synthesized PEP7 markedly inhibited angiotensin II (Ang II) -induced Erk1/2 activation in cell culture by 62% compared to a scrambled PEP7 (sPEP7) [pErk1/2/Erk1/2 (AU): Ang II, 1.000 ± 0.0, Ang II+PEP7, 0.3812 ± 0.086, Ang II+sPEP7, 1.069 ± 0.18; n=3]. Under these same conditions, PEP7 had no effect on Ang II-stimulated inositoltrisphosphate production. PEP7 also had no effect on EGF-and PMA-induced Erk1/2 activation, suggesting PEP7 selectively inhibits AT 1a R-mediated Erk1/2 signaling. PEP7 i.c.v. inhibited Ang II-induced saline intake but had no effect on water intake in male and female rats indicating PEP7 also selectively inhibits the Ang II-Erk1/2 pathway in vivo since saline drinking is Erk1/2-mediated while water drinking is not. PEP7 inhibition of Ang II-induced saline ingestion was rapidly reversed by a subsequent i.c.v. injection of an oxytocin antagonist suggesting when PEP7 blocks Ang II-stimulated Erk1/2 activation, animals no longer ingest saline to balance the continued water intake, due to the release of oxytocin and its subsequent inhibitory effects on saline drinking. PEP7 also attenuated Ang II-induced increases in arterial pressure by 35% when compared to sPEP7 at the same dose. Thus, we have identified a novel peptide encoded within the rAT 1a R E2 that selectively inhibits Erk1/2 activation resulting in physiological consequences for sodium ingestion and arterial pressure that may have implications for treating sodium-sensitive diseases like hypertension and chronic kidney disease.
Introduction
The rat angiotensin type 1 receptor (AT 1a R) plays a critical role in regulating blood pressure and electrolyte homeostasis. This G protein-coupled receptor is encoded by two distinct mRNA transcripts that are synthesized from the AT 1a R gene by alternative splicing. One of the two transcripts contains exons 1, 2 and 3 (E1, E2, E3), while the other contains E1 and E3. In the E1,2,3 transcript, the 5' leader sequence (5'LS) is comprised of E1, E2 and 52 bp of E3 (Fig. 1A) ; in the E1,3 transcript, the 5'LS includes E1 and 52 bp of E3. In both transcripts, the entire coding region and the 3' untranslated region (3'UTR) exist within E3. Therefore, the two AT 1a R mRNA transcripts that differ in the 5'LS length encode the same identical AT 1a R protein.
Despite the identical amino acid sequence of the AT 1a R in both transcripts, we previously showed that the E1,2,3 mRNA is translated less efficiently than the E1,3 mRNA (21). TAA, which is in frame with the AT 1a R coding region (Fig. 1A) . PEP7 is especially interesting since its amino acid sequence is markedly conserved in rats and mice and humans (Fig. 1B) .
The AT 1 R is one of the most versatile members of the G protein-coupled receptor family.
Upon angiotensin II (Ang II) binding, the AT 1a R mediates signal transduction through multiple signaling pathways including the phospholipase C (PLC)-inositol 1,4,5-trisphosphate (IP 3 ) (32) and extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) (20). These signaling pathways are both G protein-coupled and G protein-independent (16). To determine the effects of PEP7 on these distinct AT 1a R signaling pathways, this study investigated the pharmacological effects of PEP7 on AT 1a R-mediated IP 3 production and Erk1/2 activation in human embryonic kidney cells transiently expressing the rat AT 1a R.
To investigate the effects of PEP7 on distinct AT 1a R signaling pathways in vivo, we studied the effect of PEP7 on water and saline drinking in adult male and female rats since this is a model in which the stimulatory actions of Ang II depend upon specific signaling cascades (10) (11) (12) 14) . Indeed, the ability of Ang II to stimulate water drinking can be selectively blocked by inhibitors of protein kinase C (PKC) activity, while saline drinking is dependent upon Erk1/2 activation. Central administration of Ang II stimulates saline drinking and paradoxically, also increases the local release of oxytocin, which is a peptide that inhibits saline intake (4, 5) . We investigated the effects of PEP7 on these apparently competing actions of Ang II in the control of saline ingestion. We also examined the ability of PEP7 to modulate Ang II-induced increases in arterial pressure since AT 1 R antagonists are widely used clinically to treat hypertension.
Materials and Methods

Plasmid Construction and Site-directed Mutagenesis
The rAT 1a R transcript containing exons 1, 2 and 3 (5'LS[1,2,3]-CR-3'UTR) was cloned into the pCR3.1 expression vector (Invitrogen).
Cell Culture and Transfections
Human embryonic kidney (HEK)-293 cells were cultured and transfected with plasmid constructs as described (1).
Erk1/2 Activation
Forty eight hr after transfection, HEK-293 cells were preincubated with vehicle, PEP7, sPEP7-1, sPEP7-2, Ro-318220 or AG1478 before treatment with Ang II, epidermal growth factor (EGF) or phorbol methyl ester (PMA). Erk1/2 and pErk1/2 were determined by Western blot as described (37).
IP 3 Assay
Twenty four hr after transfection, HEK-293 cells were cultured with 2 μCi/ml myo-[ ]-Ang II competition dose response curves were conducted with saralasin, PEP7 and sPEP7-1 in isolated rat liver membranes (35) as described (18).
Saline and Water Intake experiments
In the first experiment, vehicle (0.9% NaCl:DMSO, 30:1), or sPEP7-1 (males only) or PEP7 (1.0 nmol) were injected (2 µl) via indwelling cannula (i.c.v.) in male and female rats as described (39) . Ten min later, all animals received Ang II (25 pmol/2 µl saline) by i.c.v. injection.
Thereafter, tap water and 1.5% NaCl drinking bottles were returned to the cages. Water and saline intakes were monitored visually (water bottle gradations = 1 mL). Food was returned to the cages after the 1 hr data point was collected.
In the second experiment, male rats were pretreated with PEP7 (1.0 nmol/2 µl, i.c.v) and ten min later, Ang II (25 pmol/2 µl saline) was administered as above and drinking bottles were returned to the cages. Water and saline intakes were monitored as above. After the 30 min data collection time point, vehicle (sterile saline) or the oxytocin antagonist (OVT, 8.7 nmol/2 µl) were administered and cumulative water and saline drinking were monitored as described (5, 39) .
Food was returned at the 60 min data collection time point.
Measurement of Mean Arterial Pressure (MAP)
Male SD rats were anesthetized with inactin and MAP was measured through the carotid artery as described (22). Vehicle (dimethylformamide (DMF) or PEP7 and sPEP7-1 (500 ng/kg/min) were administrated through the jugular vein prior to Ang II treatment. After pretreatment with vehicle (DMF) or 500 ng/kg/min of PEP7 or sPEP7-1 for 3 hrs, Ang II (500 ng/kg/min) was continuously infused for 30 min.
PEP7 inhibits Ang II signaling through the Erk1/2 signal transduction pathway
To determine the effects of exogenous PEP7 on AT 1a R signaling, Ang II-induced Erk1/2 activation was investigated in HEK-293 cells transfected with the AT 1a R cloned into the pCR3.1 expression plasmid (5'LS[1,2,3]-CR-3'UTR-pCR3.1). Ang II (100 nM) rapidly activated Erk1/2 phosphorylation; the maximum effect on phospho-Erk1/2 (pErk1/2) expression occurred at 5 min and thus this time point was used for the PEP7 dose response. Preincubation of the cells with PEP7 markedly attenuated Ang II-induced Erk1/2 activation under conditions in which a scrambled PEP7 (sPEP7-1) had no effect (Fig. 2A&B) . At the highest concentration tested, PEP7 inhibition was maximal after a 3 hr preincubation period.
PEP7 does not inhibit Ang II signaling through the PLC signal transduction pathway
To determine if PEP7 also inhibits Ang II-induced IP 3 
PEP7 inhibition of Erk1/2 signaling is specific to the AT 1a R
To determine if PEP7 inhibition of Erk1/2 signaling is specific to the AT 1a R, HEK-293 cells were treated with 100 ng/ml of epidermal growth factor (EGF) for 5 min or 100 ng/ml of the PKC activator, PMA, for 10 min. Prior incubation of the cells for 15 min with 1 µM AG1478 (an EGF receptor kinase inhibitor) or 10 µM Ro 31-8220 (a PKC inhibitor) inhibited EGF-and PMAinduced Erk1/2 activation, respectively (Fig. 3) . In contrast, preincubation with 2.5 µM PEP7, sPEP7-1 or sPEP7-2 for 3 hr had no effect on EGF-and PMA-stimulated Erk1/2 phosphorylation.
PEP7 does not inhibit AT 1a R binding
Liver membranes were prepared from male SD rats and radioligand binding studies with ) (Fig. 4) .
PEP7 attenuates Ang II-induced sodium but not water intake
PEP7 pretreatment (1 nmol, i.c.v.) 10 min prior had no effect on water intake induced by Ang II administration (25 pmol, i.c.v.) in both male ( Fig. 5A ) and female ( Fig. 6A ) rats. In contrast, under these conditions PEP7 pretreatment markedly inhibited saline intake. In male rats, the PEP7 inhibitory effect was observed throughout the 120 min observation period ( vs. Saline (PEP7), 2.9±0.9; p=0.10] although the decrease in saline intake (53%) was much larger than the decrease in water intake (21%). Scrambled PEP7 did not alter Ang II-induced water or saline drinking in male rats (Fig. 5A&B ).
PEP7 also inhibited saline intake in random cycling females; significant differences between vehicle and PEP7 pretreated females were observed at all time points except at 120 min (p= 0.054) (Fig. 5B) , though no significant differences were observed in cumulative saline intake between groups at 24 hr (p = 0.55)(data not shown).
Oxytocin antagonist administration restores Ang II-stimulated sodium intake in PEP7 pretreated rats
The oxytocin antagonist, OVT (8.7 nmol, i.c.v.) failed to alter water drinking in rats pretreated with either vehicle of PEP7 (Fig. 7A) . However, OVT administration did reverse the PEP7 inhibitory effect on Ang II-induced saline intake (Fig. 7B) . The reversal was rapid and the effect was already significant at 10 min following antagonist administration. Cumulative water consumed after 24 hr did not differ between groups [Intake (ml): Water (PEP7+Veh), 25.1±3.0 vs. Water (PEP7+OVT), 25.7±3.3, p=0.91], and no significant differences were observed in cumulative saline consumed over 24 hr in response to Ang II administration between these two groups [Intake (ml): Saline (PEP7+Veh), 3.0±1.1 vs. Saline (PEP7+OVT), 5.3±1.2, p=0.18].
Administration of 8.7 nmol OVT alone either 10 minutes prior to or 30 minutes following Ang II injection failed to significantly alter water or saline ingestion in a separate group of animals (data not shown).
PEP7 inhibits acute effects of Ang II on mean arterial pressure (MAP)
Acute administration of Ang II (500 ng/kg/min) via the jugular vein increased MAP in male SD rats by 60.9 ± 1.4 mmHg. Pre-treatment with PEP7 at the same dose as Ang II three hrs before Ang II administration inhibited the Ang II-mediated increases in arterial pressure by 35% when compared to sPEP7-1 at the same dose ( Fig. 8A-C) . The non-Ang II treated time control showed that MAP was indistinguishable 5 min prior and 5 min after the period during which Ang II was infused in the treatment groups (data not shown). Furthermore, there was no difference in MAP between the non-pretreated Ang II stimulated control and the sPEP7 pretreated Ang II stimulated group either before or after Ang II stimulation (data not shown).
Discussion
The AT 1 R mediates signal transduction through multiple signaling pathways (19). In fact, the AT 1 R is one of the most versatile members of the seven transmembrane spanning receptor superfamily in its ability to couple to a myriad of signaling cascades. Much research has been done on the classic AT 1 R IP 3 -calcium and PLC-diacylglycerol (DAG)-PKC signaling pathway.
Less well understood is how the receptor mediates mitogen-activated protein kinase (MAPK) signal transduction and transactivation of the EGF receptor. One of the major findings of this paper is that PEP7 inhibited Ang II-induced phosphorylation of Erk1/2 in HEK-293 cells expressing the AT 1a R (Fig. 2A&B) under conditions in which it had no effect on Ang II-induced IP 3 production (Fig. 2C) . Thus, PEP7 will be a valuable tool, as the first reported selective inhibitor of the AT 1a R-Erk signal transduction pathway, to investigate the functional consequences of this non-classical AT 1 R signaling cascade. Furthermore, use of PEP7 will complement studies using Sar protein-independent Erk1/2 pathway, which stimulates AT 1 R phosphorylation and coupling to β-arrestin resulting in a bias towards G protein-independent signaling (6, 17, 37).
The AT 1a R can activate Erk1/2 through G protein-dependent mechanisms (Fig. 9) . In the classic AT 1 R signaling cascade, within seconds the AT 1 R activates PLC producing IP 3 and DAG. DAG can then subsequently activate Erk1/2 via PKC activation (27). The finding that PEP7 did not inhibit Erk1/2 activation via the PKC activator PMA (Fig. 3A&C) under conditions in which PMA-induced PKC activation was completely inhibited by the PKC inhibitor Ro-318220 suggests PEP7 does not inhibit Erk1/2 activation via the PKC pathway. Ang II-induced G protein-mediated signaling pathways leading to Erk1/2 activation also include the Gq/11-PKC-MAPK 1 (MEK) pathway and transactivation of EGF via the EGF receptor and the MEK pathway (19). PEP7 had no effect on AG1478-sensitive EGF-induced Erk1/2 activation (Fig. 3A&B) suggesting PEP7 inhibition of Erk1/2 activation is not through transactivation of EGF via the EGF receptor and MEK pathway. Ang II can also induce Erk1/2 activation through G proteinindependent signal transduction pathways via β-arrestins and tyrosine kinases (16). Thus, PEP7 may block AT 1 R-mediated Erk1/2 activation by interfering with β-arrestin coupling of the AT 1 Rreceptor or by inhibiting further downstream in the β-arrestin pathway.
The finding that PEP7 had no effect on (Fig. 4) indicates that the peptide does not inhibit Erk1/2 activation by inhibiting ligand binding to the AT 1a R; however, it is still possible that PEP7 could act as an allosteric modulator of the receptor to cause a conformational change resulting in selective inhibition of receptor coupling to the Erk1/2 pathway without altering agonist binding or AT 1 R-G q/11 -PLC coupling to IP 3 and intracellular calcium signaling. The discovery of biased agonists of the AT 1 R support this concept since these peptides induce disparate ligand-induced receptor states of activation (16). For example, the potency of Ang II analogs is markedly increased when position 1 is substituted with the synthetic amino acid L-sarcosine (Sar) (17, 37). Furthermore, distinct differences have been uncovered in the AT 1 R structural requirements for G protein-dependent and -independent signaling cascades (2). The carboxy tail of the AT 1a R plays a key role in β-arrestin binding and thus in G protein-independent signaling (29) whereas an aspartate (D74) (13) in the second transmembrane plays a crucial role in IP 3 production through an interaction with a tyrosine (Y292) (38) in the seventh transmembrane.
A second major new finding from our study is that we have discovered a pharmacological agent that inhibits Ang II-induced sodium but not water intake (Figs. 5&6), which mirrors our in vitro studies and suggests PEP7 is the first pharmacological agent that can selectively inhibit a specific pathway of Ang II signaling in vivo. Emerging studies suggest divergent signaling cascades result in distinct Ang II-mediated behaviors. Daniels and colleagues have established the importance of Erk1/2 activation in the stimulatory action of Ang II on saline drinking by blocking that transduction cascade with the MAP-kinase inhibitor U0126, but not the PKC inhibitor chelerythrine (10) (11) (12) . Furthermore, they showed that the biased agonist, SII-Ang II, mimics Ang II stimulation of salt appetite and inhibits Ang II-mediated stimulation of IP 3 with only a minimal enhancement of water intake (11) thereby demonstrating distinctions between these two AT 1 R agonists in their receptor interactions. They also demonstrated that Ang II administration increased pERK1/2 levels in the rostral hypothalamus including the anteroventral paraventricular area, which is an area known to be important not only for water, but also for solute ingestion (7, 34).
We observed that Ang II stimulated saline drinking to a greater extent in females than in males (Figs. 5B&6B) , but we also observed that during the habituation period prior to testing, ad libitum saline drinking in females exceeded that observed in males. Regardless, PEP7 significantly blocked Ang II -induced saline ingestion in both sexes. It is possible that the Ang II -stimulated saline ingestion and PEP7 inhibitory effects are both sexually dimorphic. Cycling females express lower densities of AT 1 Rs than males in key Ang II target tissues (33). Thus, one might expect the magnitude of the effect would be greater in the sex that exhibits lower AT 1 R tissue densities. Future studies will address this possible sex differences in greater detail.
Ang II stimulates saline ingestion, but at the same time appears to increase the central release of oxytocin, a peptide that inhibits sodium appetite (5). Blackburn and colleagues have provided convincing evidence for the physiologic relevance of those actions of oxytocin (3, 4) , but if this is the case, how could these apparently conflicting actions be balanced in vivo? We hypothesized that the direct action of Ang II (on yet to be identified neuronal populations in the forebrain) in stimulating saline drinking predominates over oxytoxin-mediated inhibition of sodium appetite. In this scenario, the peptide to balances the ingestion of solute free water with appropriate amounts of osmotically active ingestate. When the Erk1/2 signal transduction cascade activated by Ang II via the beta-arrestin pathway is blocked, as here by PEP7 administration, the inhibitory action via oxytocin release would then hold saline drinking in check, even in the face of continued water ingestion and potential hemodilution. If this is the case, then antagonism of the action of the endogenous oxytocin released in response to Ang II should reverse the inhibition and the animals should then consume saline. This is what we observed and in fact the reversal was robust and rapid and appeared within the first five min following OVT administration (Fig. 7) . Importantly, these studies provide insight into the balance of stimulatory and inhibitory effects of downstream signaling circuits activated by Ang II. Thus we are hypothesizing that Ang II acting via cells in which the MAP-kinase pathway is initiated drives a predominating stimulatory effect on saline ingestion and that this effect overwhelms the peptide's action to release oxytocin. In the absence of MAP-kinase activation (i.e. PEP7 inhibition), the effect of oxytocin to hold saline intake in check is uncovered. Our results support the hypothesis that Ang II stimulation of oxytocin release is via the G protein-dependent signaling pathway and therefore not affected by MAP-kinase inhibition.
Our third major finding in this study is that PEP7 can lower the arterial pressure response to Ang II stimulation (Fig. 8) . This observation suggests Ang II-dependent Erk1/2 activation contributes to blood pressure regulation. Hypertension and associated diseases including stroke (9), atherosclerosis (36) and chronic kidney disease (8) remain the number one cause of death throughout the world (25, 28). In the United States, more than fifty percent of hypertensive patients do not have their blood pressure well controlled. Suboptimal blood pressure control is in part due to poor patient compliance because of the adverse side effects (e.g., dizziness, headache, cough and sexual dysfunction) associated with the widely prescribed angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs).
Lack of control is also due to the frequent need for more than one medication to achieve target blood pressure (23) and it is especially common in patients with salt-sensitive hypertension.
Thus, the discovery of PEP7 may lead to novel therapeutics for attenuating hypertension.
The finding that the synthesized peptide has selective inhibitory effects on AT 1 Rmediated Erk1/2 activation both in vitro and in vivo under conditions in which scrambled peptides have no effect strongly suggests the sORF encoding PEP7 plays a physiological role in modulating AT 1 R actions. Furthermore, the fact that the encoded peptide is highly conserved across species (Fig. 1B) lends supports that indeed there is a physiological role for the PEP7 sORF; however, even if the peptide is not translated in vivo, the fact that PEP7 has pharmacological actions in vivo on sodium appetite and blood pressure makes this peptide an interesting newly discovered modulator of the critically important renin-angiotensin system. Given the hydrophobic nature of the peptide, we hypothesize that PEP7 administered exogenously crosses the cell membrane and interferes with AT 1 R coupling to the non-G proteindependent β-arrestin-2 pathway either directly or indirectly.
Elucidating the actions of a novel peptide encoded within the 5'LS of the AT 1a R has ramifications for other seven transmembrane spanning receptors since sORFs are widely encountered in this protein super family (26, 31) as well as in other key proteins like protooncogenes, signaling molecules and immune mediators (40) . Yet, the actions of peptides encoded within these sORF's remain poorly understood. Forty percent of all prescription drugs are targeted towards the seven transmembrane spanning receptor class of proteins (15), which is more than any other family of proteins (30) . Therefore, this research may have implications for developing novel therapeutics across a large family of drug targets. 
